I think it's realistic to expect a stunted take-up whilst competitors fruitlessly try to ward off a game changer.
In the medium term, however, it cannot not claim the entire market (at least those that can afford it) without serious corruption/dereliction of medical duties.
Unless, of course, a better product comes along. Possible, but not likely.
world congress of cardiology 2014 melbourne , page-21
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.25 |
Change
0.740(5.48%) |
Mkt cap ! $301.2M | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.25 | $13.35 | $309.6K | 22.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1150 | $14.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.25 | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |